KLK3 and prostate cancer: In the 96 patients in the hormone therapy plus celecoxib group who reported an FFS event, the first event was PSA failure in 75 (78%), metastases in 15 (16%), local progression in two (2%) and prostate-cancer-related death in four (4%).